143 related articles for article (PubMed ID: 8914196)
1. Characterization, formulation, and stability of Neupogen (Filgrastim), a recombinant human granulocyte-colony stimulating factor.
Herman AC; Boone TC; Lu HS
Pharm Biotechnol; 1996; 9():303-28. PubMed ID: 8914196
[No Abstract] [Full Text] [Related]
2. Doping control analysis of filgrastim in equine plasma and its application to a co-administration study of filgrastim and recombinant human erythropoietin in the horse.
Ho EN; Kwok WH; Lau MY; Wong AS; Lam KK; Stewart BD; Wan TS
J Chromatogr A; 2014 Apr; 1338():92-101. PubMed ID: 24636755
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product.
Sörgel F; Lerch H; Lauber T
BioDrugs; 2010 Dec; 24(6):347-57. PubMed ID: 20873878
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte colony stimulating factors: how different are they? How to make a decision?
Martin-Christin F
Anticancer Drugs; 2001 Mar; 12(3):185-91. PubMed ID: 11290864
[TBL] [Abstract][Full Text] [Related]
5. [Recombinant granulocyte-colony stimulating factor (filgrastim): optimization of conjugation with polyethylene glycol].
Puchkov IA; Kononova NV; Bobruskin AI; Bairamashvili DI; Mart'ianov VA; Shuster AM
Bioorg Khim; 2012; 38(5):545-54. PubMed ID: 23342488
[TBL] [Abstract][Full Text] [Related]
6. A new site-specific monoPEGylated filgrastim derivative prepared by enzymatic conjugation: Production and physicochemical characterization.
Scaramuzza S; Tonon G; Olianas A; Messana I; Schrepfer R; Orsini G; Caliceti P
J Control Release; 2012 Dec; 164(3):355-63. PubMed ID: 22735238
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim.
Skrlin A; Radic I; Vuletic M; Schwinke D; Runac D; Kusalic T; Paskvan I; Krsic M; Bratos M; Marinc S
Biologicals; 2010 Sep; 38(5):557-66. PubMed ID: 20637652
[TBL] [Abstract][Full Text] [Related]
8. Monitoring Effects of Excipients, Formulation Parameters and Mutations on the High Order Structure of Filgrastim by NMR.
Aubin Y; Hodgson DJ; Thach WB; Gingras G; Sauvé S
Pharm Res; 2015 Oct; 32(10):3365-75. PubMed ID: 26043856
[TBL] [Abstract][Full Text] [Related]
9. Comparison between biosimilar filgrastim vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network.
Marchesi F; Cerchiara E; Dessanti ML; Gumenyuk S; Franceschini L; Palombi F; Pisani F; Romano A; Spadea A; Pupo L; Annibali O; La Malfa A; Arcese W; Mengarelli A
Br J Haematol; 2015 Apr; 169(2):293-6. PubMed ID: 25371286
[No Abstract] [Full Text] [Related]
10. Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action.
Lyman GH
Expert Opin Biol Ther; 2005 Dec; 5(12):1635-46. PubMed ID: 16318427
[TBL] [Abstract][Full Text] [Related]
11. Oxidation of recombinant methionyl human granulocyte colony stimulating factor.
Reubsaet JL; Beijnen JH; Bult A; Hop E; Scholten SD; Teeuwsen J; Underberg WJ
J Pharm Biomed Anal; 1998 Jun; 17(2):283-9. PubMed ID: 9638581
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.
Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial.
Lubenau H; Bias P; Maly AK; Siegler KE; Mehltretter K
BioDrugs; 2009; 23(1):43-51. PubMed ID: 19344191
[TBL] [Abstract][Full Text] [Related]
14. Purity assessment of recombinant human granulocyte colony-stimulating factor in finished drug product by capillary zone electrophoresis.
Benković G; Skrlin A; Madić T; Debeljak Z; Medić-Šarić M
Electrophoresis; 2014 Sep; 35(18):2608-14. PubMed ID: 24913917
[TBL] [Abstract][Full Text] [Related]
15. Analytical techniques and bioactivity assays to compare the structure and function of filgrastim (granulocyte-colony stimulating factor) therapeutics from different manufacturers.
Levy MJ; Gucinski AC; Sommers CD; Ghasriani H; Wang B; Keire DA; Boyne MT
Anal Bioanal Chem; 2014 Oct; 406(26):6559-67. PubMed ID: 24264620
[TBL] [Abstract][Full Text] [Related]
16. Sterility of unit dose syringes of filgrastim and sargramostim.
Singh RF; Corelli RL; Guglielmo BJ
Am J Hosp Pharm; 1994 Nov; 51(22):2811-2. PubMed ID: 7531941
[No Abstract] [Full Text] [Related]
17. Characterisation of the site-specific monoPEGylated rhG-CSF analogue pegteograstim.
Hong J; Lee B; Kang K; Lee SH; Ryu J; Jung G; Oh J; Jo EC; Kim CW
Biologicals; 2018 Jan; 51():54-61. PubMed ID: 29107446
[TBL] [Abstract][Full Text] [Related]
18. Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.
Pettengell R; Bias P; Mueller U; Lang N
Support Care Cancer; 2016 Jun; 24(6):2677-84. PubMed ID: 26780505
[TBL] [Abstract][Full Text] [Related]
19. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers.
Lubenau H; Sveikata A; Gumbrevicius G; Macijauskiene J; Fokas V; Kazlauskas S; Janulionis V
Int J Clin Pharmacol Ther; 2009 Apr; 47(4):275-82. PubMed ID: 19356394
[TBL] [Abstract][Full Text] [Related]
20. [Biosimilar filgrastim: from development to record].
García Alfonso P
Farm Hosp; 2010 Mar; 34 Suppl 1():19-24. PubMed ID: 20920854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
